Ladarixin as Adjunctive Therapy to Improve Insulin Sensitivity and Glucometabolic Outcomes in Type 1 Diabetes

Summary

Objectives Primary study objective: To determine whether orally-administered ladarixin versus placebo adjunctive therapy improves insulin sensitivity in overweight, insulin-resistant (IR) type 1 Diabetic (T1D) adult subjects. Secondary study objectives: To determine whether orally-administered ladarixin versus placebo adjunctive therapy is safe and well-tolerated in overweight, IR T1D adult subjects.

Timeline

Start

2021-09-30

Primary completion

2023-06

Completion

2023-06

Outcome

Outcome not reported

Stopped (Enrollment): “Dompé decided to withdraw LDX0121 following an internal re-planning and an extensive review of the study design. At the time of withdrawal, no site had been activated and the drug had not been sent to investigators. No patients had been enrolled.”

Drugs

Indications